Chen Manman, Xing Jingwei, Pan Danqing, Gao Pengfei
Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Department of Traditional Chinese Medicine, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Front Microbiol. 2021 Dec 24;12:793854. doi: 10.3389/fmicb.2021.793854. eCollection 2021.
As a manifestation of metabolic syndrome in the liver, non-alcoholic fatty liver disease (NAFLD) has become the top cause of liver disease in many countries. Recent studies have shown that intestinal microbiota disorder plays an important role in the occurrence and development of NAFLD and that regulating intestinal microbiota provides a new option for NAFLD treatment. In addition, research indicates that risk of NAFLD increases as body mass index rises, and interventions that reduce body weight and change diet can help to lower the incidence of NAFLD. Studies have found that 919 syrup may effectively treat NAFLD in rats by improving liver function and lipid metabolism and regulating body weight and feed intake, however, its potential toxicity and the specific mechanism by which it controls this disease require further exploration. This study assesses both the toxicity of 919 syrup and its regulatory effect on the appetite-related Ghrelin pathway and intestinal microbiota of rats with NAFLD. Results indicate that 919 syrup has no obvious side-effects on body weight, feed intake, blood glucose level, hepatorenal function, and liver tissue structure of normal rats. Moreover, 919 syrup can reverse abnormal changes to expression of Ghrelin pathway genes related to appetite in both the brain and stomach and repair alterations to the intestinal microbiota in rats with NAFLD. This herbal medicine is a safe and promising therapeutic drug for the treatment of NAFLD.
作为肝脏代谢综合征的一种表现形式,非酒精性脂肪性肝病(NAFLD)已成为许多国家肝病的首要病因。最近的研究表明,肠道微生物群紊乱在NAFLD的发生和发展中起重要作用,调节肠道微生物群为NAFLD治疗提供了新的选择。此外,研究表明,NAFLD的风险随着体重指数的升高而增加,减轻体重和改变饮食的干预措施有助于降低NAFLD的发病率。研究发现,919糖浆可能通过改善肝功能和脂质代谢以及调节体重和采食量有效治疗大鼠的NAFLD,然而,其潜在毒性及其控制这种疾病的具体机制需要进一步探索。本研究评估了919糖浆对NAFLD大鼠的毒性及其对食欲相关的胃饥饿素途径和肠道微生物群的调节作用。结果表明,919糖浆对正常大鼠的体重、采食量、血糖水平、肝肾功能和肝组织结构无明显副作用。此外,919糖浆可以逆转大脑和胃中与食欲相关的胃饥饿素途径基因表达的异常变化,并修复NAFLD大鼠肠道微生物群的改变。这种草药是一种安全且有前景的治疗NAFLD的药物。